Internal Ethics Committee holds debate to inform regulatory review of Alzheimer’s drugs
Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). “Science precedes by open debate and discussion,” said Jason Karlawish, MD, who moderated the event and is co-chair of the ACTC Internal Ethics Committee. The goal of the debate was to inform the Alzheimer’s field about regulatory approaches that have been applied in the reviews of the drugs aducanumab, lecanemab, and donanemab. At the conclusion of the debate, audience members voted “yes” or “no” in response to the question “PET is a suitable surrogate endpoint?” Only 25% of audience members voted “yes.”
